{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:41:06Z","timestamp":1792456866567,"version":"4.5.0"},"reference-count":9,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100020948","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Elecoglipron (AZD5004\/ECC5004) is an oral small\u2010molecule glucagon\u2010like peptide\u20101 receptor agonist (GLP\u20101 RA) in development for weight management in people living with obesity or overweight and type 2 diabetes. This study aimed to characterize the pharmacokinetics (PK) profiles of two formulations of elecoglipron under fed and fasted conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assessed the PK profiles, safety and tolerability of two formulations of elecoglipron, 50\u2009mg, under fed and fasted conditions in healthy participants in a phase 1, open\u2010label, randomized, single\u2010dose, fixed\u2010sequence, crossover study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 23 participants screened, 14 were randomized to elecoglipron and 13 (92.9%) completed the study. The half\u2010life for both formulations under fasted and fed conditions ranged between 20.7 and 21.2\u00a0h. Between the fed (reference) and fasted groups, geometric mean ratios (GMR) and 90% confidence intervals (CI) for the F1 formulation: area under the plasma\u2013concentration curve (AUC) from time zero to the last measurement (AUC\n                      <jats:sub>0\u2013last<\/jats:sub>\n                      ) was 0.96 (0.82, 1.12), AUC from time zero extrapolated to infinity (AUC\n                      <jats:sub>0\u2013inf<\/jats:sub>\n                      ) was 0.95 (0.82, 1.11), and maximum plasma concentration (C\n                      <jats:sub>max<\/jats:sub>\n                      ) was 1.15 (0.90, 1.46). Similar results were observed for F2 in the fed and fasted groups. Safety and tolerability were comparable for the two formulations. The most common AEs were gastrointestinal (nausea, vomiting, dyspepsia, abdominal discomfort) and mostly mild in severity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Elecoglipron demonstrated a PK profile supportive of once\u2010daily dosing and may be administered under fed or fasted conditions. These findings support the continuing clinical development of elecoglipron. The trial is registered at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      (NCT06268145). The trial was first registered on 20 February 2024.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70852","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:20:36Z","timestamp":1792455636000},"source":"Crossref","is-referenced-by-count":0,"title":["Phase 1, open\u2010label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2153-0842","authenticated-orcid":false,"given":"Jianfeng","family":"Xu","sequence":"first","affiliation":[{"name":"Eccogene Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Haggag","sequence":"additional","affiliation":[{"name":"Anaheim Clinical Trials LLC  Anaheim California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Butcher","sequence":"additional","affiliation":[{"name":"Eccogene Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Liu","sequence":"additional","affiliation":[{"name":"Eccogene (Shanghai) Co. Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"Eccogene Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Sun","sequence":"additional","affiliation":[{"name":"Eccogene (Shanghai) Co. Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7339-2725","authenticated-orcid":false,"given":"Aruni","family":"Jha","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology &amp; Quantitative Pharmacology, Clinical Pharmacology &amp; Safety Sciences, BioPharmaceuticals R&amp;D AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2278-4478","authenticated-orcid":false,"given":"Hongtao","family":"Yu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology &amp; Quantitative Pharmacology, Clinical Pharmacology &amp; Safety Sciences, BioPharmaceuticals R&amp;D AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis","family":"Khan","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology &amp; Quantitative Pharmacology, Clinical Pharmacology &amp; Safety Sciences, BioPharmaceuticals R&amp;D AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria E. R.","family":"Parker","sequence":"additional","affiliation":[{"name":"Late\u2010Phase Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Tannergren","sequence":"additional","affiliation":[{"name":"Pharmaceutical Technology and Development AstraZeneca  M\u00f6lndal Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Pan","sequence":"additional","affiliation":[{"name":"Eccogene (Shanghai) Co. Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Eccogene (Shanghai) Co. Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingye","family":"Zhou","sequence":"additional","affiliation":[{"name":"Eccogene Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1798099"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.838410"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645507"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17020238"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.ady2624"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","unstructured":"WangY StoferR WangH et al.Adherence patterns of oral vs injectable GLP\u20101 receptor agonists: a national real\u2010world analysis of commercial claims data 2010\u20132021. PREPRINT (Version 1) 2025.","DOI":"10.21203\/rs.3.rs-6586064\/v1"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16047"},{"key":"e_1_2_10_10_1","unstructured":"HaggagAZ PugnussatS XuJ et al.Safety tolerability and pharmacokinetics of AZD\/ECC5004 an oral small molecule GLP\u20101 receptor agonist. Obesity Week; November 3\u20136 2024.2024. San Antonio Texas."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70852","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70852","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:20:37Z","timestamp":1792455637000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":9,"alternative-id":["10.1002\/bcp.70852"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70852","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"article-number":"bcp.70852"}}